Cognetivity Neurosciences Releases Latest Version of AI-powered Brain Health Assessment Platform

With global interest in AI at an all-time high, the recent update of Cognetivity’s flagship medical device reinforces the company’s ongoing commitment to be at the forefront of AI in healthcare

Vancouver, British Columbia–(Newsfile Corp. – February 14, 2023)- cognitive neurosciences ltd (CSE: CGN) (OTCQB: CGNSF) (FSE: 1UB) (the “Company” or “Cognetivity”)a technology company that has developed a unique brain health screening platform for use in medical, commercial and consumer settings, is pleased to announce that it has released an updated version of its flagship tool, CognICA™.

CognICA is a unique brain health assessment and monitoring platform: powered by artificial intelligence (AI), FDA registered and CE marked, and deployed commercially in North America, East and Southeast Asia, the Middle East and the UK Health Service (NHS) .

Cognetivity’s technology uses AI and machine learning (ML) techniques to detect the earliest signs of cognitive impairment by providing a fast, sensitive and objective measurement of brain function. This enables CognICA™ to facilitate the early identification of individuals with brain health issues, when interventions are most effective, as well as to support their long-term treatment management and monitoring.

Crucially, as a fundamentally AI and ML-based tool, CognICA can be continuously expanded and improved over time and trained with more data from an increasing number of global deployments to create increasingly refined, disease-specific models. In the case of Alzheimer’s disease, for example, the company already holds a patent covering the use of an AI-based system to estimate levels of key biomarkers of neurodegeneration in the brain, such as amyloid-β (Aβ) protein.

The tool is tablet-based, self-governing, and independent of language and educational biases, making it extremely effective for comprehensive, scaled screening programs across geographies. In addition to a number of improvements, the latest version of CognICA includes a local data storage capability, facilitating deployment in an expanded range of territories, thus expanding the potential market for the technology. It also allows for unlimited scaling, ensuring users benefit from a fast and efficient experience regardless of user load.

dr Commenting on the announcement, Sina Habibi, CEO of Cognetivity, “At Cognetivity, we have always been committed to driving excellence in healthcare and to playing the important role that AI must play in realizing this transformation. We are excited to release the latest upgrade to our flagship platform, which reaffirms our commitment to providing an outstanding, powerful tool that can revolutionize clinical practice and the lives of millions of patients around the world.”

About Cognitivity Neurosciences Ltd.

Cognetivity is a technology company that has developed a cognitive testing platform for use in medical, commercial and consumer environments. Cognetivity’s ICA uses artificial intelligence and machine learning techniques to detect the earliest signs of cognitive impairment by testing the performance of large areas of the brain. The ICA is currently available for clinical use in the US, UK, Europe and the Middle East, with regulatory approval for other regions planned for 2023.


“Sina Habibi”
Sina Habibi

Chief Executive Officer and Director


Certain statements contained in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those identified by the words “anticipate,” “assume,” “believe,” “plan,” “estimate,” “expect” , “intend”, “may”, “should” and similar expressions as they refer to the Company or its management. The forward-looking statements are not historical facts, but instead reflect current expectations as to future results or events. This press release contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Such statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions about current and future business strategies and the environment in which the company will operate in the future. The Company assumes no responsibility to update or revise any forward-looking information to reflect new events or circumstances, except as required by law. Readers should not place undue reliance on the Company’s forward-looking statements.

The Canadian Securities Exchange accepts no responsibility for the adequacy or accuracy of this press release.

For more information: Please visit: or contact: [email protected]; For media inquiries please contact [email protected].

To view the source version of this press release, please visit


Leave a Reply

Your email address will not be published. Required fields are marked *